Sort by
Refine Your Search
-
. Depending on available funding, one of the positions may be specifically targeted at candidates interested in the scaling regimes of deep networks. Basic Qualifications A PhD is required. We seek candidates
-
in neural interfacing. Projects involve peripheral nerve regeneration, mechanoreceptor-specific targeting, and surgical reconstruction for prosthetic interfacing. Deadline for application: Apr 15, 2025
-
from the cerebellum and from output targets such as the cerebellar nuclei, (2) experience studying cerebellar-dependent behaviors, and (3) anatomical approaches and (4) slice recordings. The successful
-
process. We use a combination of human and mouse in vivo and in vitro studies to carry out chemical screening and transcriptional profiling analyses to evaluate potential therapeutics related to targeting
-
. Depending on available funding, one of the positions may be specifically targeted at candidates interested in the scaling regimes of deep networks. Basic Qualifications A PhD is required. We seek candidates
-
to contribute to ongoing projects and/or explore new research directions within the group. Depending on available funding, one of the positions may be specifically targeted at candidates interested in the scaling
-
in neural interfacing. Projects involve peripheral nerve regeneration, mechanoreceptor-specific targeting, and surgical reconstruction for prosthetic interfacing. Deadline for application: Apr 15, 2025
-
advertising and marketing efforts. We have divided the Cookies we use into the following categories: Strictly Necessary, Performance, Functional, and Targeting. Under each category heading below you will find a
-
characterization of neofunctionalized enzymes in plant metabolism, 2) elucidation and engineering of biosynthetic pathways for high-value molecules from plants, and 3) identifying the native targets of bioactive
-
unique combination of techniques to understand why certain retinal cells stay strong in glaucoma while others don’t. Learn More How Targeting a Molecular ‘Switch’ Could Inspire New Macular Degeneration